已知胆固醇结石患者在应用鹅去氧胆酸(简称CDCA)后,肝中HMG-CoA还原酶(简称HMG-CoAR,是内源性胆固醇合成的限速酶)及胆固醇7α-羟化酶(简写7α-羟化酶,是胆汁酸合成的限速酶)活力均有降低。本文研究胆石症患者在CDCA治疗前和治疗期间的肝脏中此两酶的活力及胆汁中脂质(胆固醇、磷脂及胆汁酸)的变化,并与无胆石症的对照者相比较,探讨胆石症发病机制及CDCA溶胆石的机理。研究对象为12例无症状的胆囊透光结石及6例无胆石、无胃肠道病变的对照者。除1例病人是东方人之外,其余对象均系白人。患者在治疗期间均给以正常的、既不限制胆固醇也不用高胆固醇的饮食,也不用任何可以改变胆汁中脂质的药物,血清转氨酶、碱性磷酸 Known cholesterol gallstone patients in the application of chenodeoxycholic acid (CDCA), the liver HMG-CoA reductase (referred to as HMG-CoAR, is the rate of endogenous cholesterol synthesis rate) and cholesterol 7α-hydroxylase Abbreviations 7α-hydroxylase, is the rate-limiting enzyme for bile acid synthesis) activity decreased. In this paper, the cholelithiasis patients in the CDCA before and during treatment of the liver activity of these two enzymes and bile lipid (cholesterol, phospholipid and bile acid) changes, and compared with non-cholelithiasis, cholelithiasis Pathogenesis and mechanisms of CDCA-induced gallstone. The subjects were 12 asymptomatic gallbladder translucent stones and 6 cases of non-gallstone, no gastrointestinal lesions in the control group. Except 1 patient was Oriental, the rest were white. During treatment, patients were given a normal diet that neither cholesterol nor high cholesterol, nor any drugs that changed the lipid in the bile. Serum transaminases, alkaline phosphatase